BackBellicum Pharmaceuticals Overview

Bellicum Pharmaceuticals Total Liabilities

Track Bellicum Pharmaceuticals's total liabilities ($34M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$33.87M
42.39% YoYΔ $10.08M vs prior year quarter

Peer average

Loading

Bellicum Pharmaceuticals Total Liabilities History

Loading

Bellicum Pharmaceuticals vs. peers: Total Liabilities Comparison

Loading

Bellicum Pharmaceuticals Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Bellicum Pharmaceuticals (BLCM) FAQ

Bellicum Pharmaceuticals's total liabilities stands at $34M as of September 2023. That compares with $24M in the prior-year period — up 42.4% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Bellicum Pharmaceuticals reported $34M in total liabilities versus $24M a year earlier — a 42.4% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $24M in the prior-year period — up 42.4% year over year. Sustained growth in total liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Bellicum Pharmaceuticals's total liabilities evolved across reporting periods, while the comparison chart places BLCM next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total liabilities is commonly used to spot outliers. Bellicum Pharmaceuticals's reading of $34M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.